Last checked at 9 Jul 2008 07:00
| For immediate release | 9 July 2008 |
ALLIANCE PHARMA PLC
("Alliance Pharma" or "the Company")
Pre-close Trading Update
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces a pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2008.
Trading is in line with expectations with half year sales expected to be in the region of £9.9 million, a 27% increase on the first half last year, which in part reflects the resolution of third party supply issues.
As a result, profit before tax for the half year is expected to be in the region of £1.0 million, demonstrating the continuing success of the steps initiated last year to substantially improve profitability. Additionally, post-tax profit is likely to be enhanced by potential R&D tax credits announced on 1 July 2008.
The Company's interim results are due to be announced on 10 September 2008.
For further information:
| Alliance Pharma plc | + 44 (0) 1249 466966 |
| John Dawson, Chief Executive | |
| Richard Wright, Finance Director | |
| www.alliancepharma.co.uk | |
| | |
| Buchanan Communications | + 44 (0) 20 7466 5000 |
| Mark Court / Rebecca Skye Dietrich | |
| | |
| Numis Securities Limited | + 44 (0) 20 7260 1000 |
| Nominated Adviser: Michael Meade / Brent Nabbs | |
| Corporate Broking: David Poutney | |